Abstract
Background: Combination therapy with catheter ablation of the cavo‐tricuspid isthmus and continued drug therapy, that is, “hybrid therapy,” in patients with atrial fibrillation (AF) and drug‐induced atrial flutter (AFL) is reported to be an alternative means of achieving and maintaining sinus rhythm. With respect to choosing this method among the rhythm control therapies, its long‐term efficacy and the prevalence of AFL in patients with AF are very important and have not been fully elucidated.
Hypothesis: The purpose of this study was to investigate the long‐term effectiveness of this hybrid therapy and the dose prevalence inIc drug‐induced AFL.
Methods: The subjects were 89 patients (aged 62.4 years, 72 men) with episodes of AF (paroxysmal type: 65, persistent type: 11, permanent type: 13). After 4 weeks of oral pilsicainide administration, the dose was increased in those with no documented AFL. The patients who experienced AFL with pilsicainide (Ic‐AFL) underwent ablation.
Results: Pilsicainide administration resulted in the common type AFL in 17 patients (19.1%). The pilsicainide plasma concentration in the patients with Ic‐AFL was significantly higher than in those without AFL (0.79 ± 0.41 vs. 0.51 ± 0.24 μg/ml, respectively, p < 0.01). During a 10–54 (mean 37 ± 14) month follow‐up period, sinus rhythm was maintained in 10 of 12 patients after successful ablation followed by continued antiarrhythmic drug administration.
Conclusions: Hybrid therapy with ablation and high doses of pilsicainide was useful in maintaining sinus rhythm in some selected patients with AF and drug‐induced AFL.
Keywords: atrial fibrillation, class Ic drug, atrial flutter, pilsicainide, catheter ablation, hybrid therapy
Full Text
The Full Text of this article is available as a PDF (39.7 KB).
References
- 1. Cheng TO: Atrial flutter during quinidine therapy of atrial fibrillation. Am Heart J 1956; 52: 273–289 [DOI] [PubMed] [Google Scholar]
- 2. Feld GH, Chen PS, Nicod P, Fleck RP, Mezer D: Atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990; 66: 378–382 [DOI] [PubMed] [Google Scholar]
- 3. Falk RH: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141–150 [DOI] [PubMed] [Google Scholar]
- 4. Friedman P, Stevenson WG: Proarrhythmia. Am J Cardiol 1998; 82: 50N–58N [DOI] [PubMed] [Google Scholar]
- 5. El‐Harari MB, Adams PC: Atrial flutter with 1: 1 atrioventricular conduction caused by propafenon. PACE 1998; 21: 1999–2001 [DOI] [PubMed] [Google Scholar]
- 6. Crijns HJ, van Gelder IC, Lie KI: Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988; 62: 1303–1306 [DOI] [PubMed] [Google Scholar]
- 7. Murdock CJ, Kyles AE, Lai‐Wah JA, Qi A, Vorderbrugge S, Kerr CR: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66: 755–757 [DOI] [PubMed] [Google Scholar]
- 8. Falk RH, Fogel RI: Flecainide. J Cardiovasc Electrophysiol 1994; 5: 964–981 [DOI] [PubMed] [Google Scholar]
- 9. Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F, Azegami K, Hiejima K: Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol 2001; 34: 65–72 [DOI] [PubMed] [Google Scholar]
- 10. Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME: Hybrid pharmacologic and ablative therapy. Anovel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: 462–469 [DOI] [PubMed] [Google Scholar]
- 11. Schumacher B, Jung W, Lewalter T, Vahlhaus C, Wolpert C, Luderitz B: Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999; 83: 710–713 [DOI] [PubMed] [Google Scholar]
- 12. Nabar A, Rodrigez LM, Timmermans C, Smeets JLRM, Wellens HJJ: Radiofrequency ablation of “class IC atrial flutter” in patients with resistant atrial fibrillation. Am J Cardiol 1999; 83: 785–787 [DOI] [PubMed] [Google Scholar]
- 13. Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN, Ding YA, Chang MS, Chen SA: Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: Electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol 1999; 10: 1180–1187 [DOI] [PubMed] [Google Scholar]
- 14. Nabar A, Rodriguez LM, Timmermans C, van den Dool A, Smeets JLRM, Wellens HJJ: Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patient groups having type I atrial flutter with or without associated fibrillation. Circulation 1999; 99: 1441–1445 [DOI] [PubMed] [Google Scholar]
- 15. Reithmann C, Hoffmann E, Spitzlberger G, Dorwarth U, Gerth A, Remp T, Steinbeck G: Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J 2000; 21: 565–572 [DOI] [PubMed] [Google Scholar]
- 16. Reithmann C, Dorwarth U, Dugas A, Hahnefeld A, Ramamurthy S, Remp T, Steinbeck G: Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug‐induced atrial flutter. Eur Heart J 2003; 24: 1264–1272 [DOI] [PubMed] [Google Scholar]
- 17. Aisaka K, Hidaka T, Inomata N: N‐(2,6‐dimethylphenyl)‐8‐pyrrolizidineac‐etamide hydrochloride hemihydrate 8SUN 1165): A new potent and long‐acting antiarrhythmic agent. Arzneimittelforschung/Drug Res 1985; 35: 1239–1245 [PubMed] [Google Scholar]
- 18. Hattori Y, Inomata N, Aisaka T, Ishikawa T: Electrophysiological action of N‐(2,6‐dimethylphenyl)‐8‐pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986; 8: 998–1002 [DOI] [PubMed] [Google Scholar]
- 19. Ino T, Atarashi H, Hayakawa H: Electrophysiologic and hemodynamic effects of SUN 1165, a new antiarrhythmic agent In Current Topics in Antiarrhythmic Agents, p. 219 (Eds: Toyama J, Hondeghem LM.), Tokyo: Excepta Medica, 1989. [Google Scholar]
- 20. Atarashi H, Inoue H, Hiejima K, Hayakawa H: Conversion of recent‐onset atrial fibrillation by a single oral dose of pilsicainide (pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol 1996; 78: 694–697 [DOI] [PubMed] [Google Scholar]
- 21. Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K, and the Kanagawa Arrhythmia Task Force Investigators : Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo‐controlled, multicenter study. Am Heart J 2000; 140: 437–444 [DOI] [PubMed] [Google Scholar]
- 22. Stabile G, Simone AD, Turco P, Rocca VL, Nocerino P, Astarita C, Maresca F, Matteis CD, Napoli TD, Stabile E, Vitale DF: Response to flecainide infusion predicts long‐term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 1639–1644 [DOI] [PubMed] [Google Scholar]
- 23. Schumacher B, Spehl S, Haase KK, Pfleger S, Wolpert C, Juncker M, Gaudron P, Jung W, Luderitz B: “Hybrid” therapy of atrial fibrillation: Patients selection by IV administration of class 1c antiarrhythmic drugs. Preliminary results of a prospective randomized trial. PACE 2000; 23: II‐651 [Google Scholar]